Clinical prognostic factors of bilateral synchronous renal cancer

Cover Page

Cite item

Full Text

Abstract

The aim of the study is to assess the positive and negative prognostic factors of survival in patients with bilateral synchronous renal cancer (BRC). Materials and methods. The study was conducted on the basis of N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation. Cohort of patients with the synchronous BRC consisted of 160 patients between 1996 and 2014. All patients after finishing treatment were observed on an ambulatory basis during the period from 11 months to 12 years (median follow-up 81.05±46.7 months). We studied factors affecting 5-year survival rate, both positive and negative. Statistical analysis of the obtained results carried out using generally accepted statistical methods such as SPSS 23.0 - block of programs for Windows. Results. In case of synchronous BRC in 2/3 (65%) of patients the first kidney was operated on using organ-preserving surgery, in 1/4 of patients (n=21, 26.2%) both kidneys were operated on using organ-preserving surgery. In case of synchronous renal cancer the best results of survival, but without statistical significance (p=0.112) had patients with bilateral renal cancer who operated on using organ-preserving surgery. The 10-year overall survival in this group of patients was 90.5% in comparison with 62.5% - when nephrectomy was performed on the first stage and 76.4% in patients who had nephrectomy performed because of the renal cancer in the second kidney. Conclusions. The main factors affecting the 5-year survival rate of patients with synchronous BRC were: smoking, primary tumor size, age and type of surgery.

About the authors

M I Komarov

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: 0050037@mail.ru
канд. мед. наук, науч. сотр. урологического отд-ния 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

V B Matveev

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

чл.-кор. РАН, д-р мед. наук, проф., зав. урологическим отд-нием, зам. дир. по научной и инновационной работе 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

M I Volkova

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

д-р мед. наук, вед. науч. сотр. урологического отд-ния 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

I G Komarov

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

д-р мед. наук, вед. науч. сотр. урологического отд-ния диагностики опухолей 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

V A Ridin

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

аспирант урологического отд-ния 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

References

  1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49 (6): 1374-403. doi: 10.1016/j.ejca.2012.12.027
  2. Đozić J, Djozic S, Bogdsnovic J et al. Preservation surgery in patients with localized renal cell cancer-Nephron Sparing Surgery. Acta chirurgica Iugoslavica 2014; 61 (1): 45-9.
  3. Shuch B, Singer E.A, Bratslavsky G. The surgical approach to multifocal renal cancers: hereditary syndromes, ipsilateral multifocality, and bilateral tumors. Urol Clin North Am 2012; 39 (2): 133-48. doi: 10.1016/j.ucl.2012.01.006
  4. Singer E.A, Vourganti S, Lin K.Y et al. Outcomes of Patients with Surgically Treated Bilateral Renal Masses and a Minimum of 10 Years of Followup. J Urol 2012; 188 (6): 2084-8. doi: 10.1016/j.juro. 2012.08.038
  5. Creatinine Clearance (Cockcroft-Gault Equation). https://www. mdcalc.com/creatinine-clearance-cockcroft-gault-equation#creator-insights
  6. Bratslavsky G, Linehan W.M. Long-term management of bilateral, multifocal, recurrent renal carcinoma. Nat Rev Urol 2010; 5: 267-75.
  7. Parkin D.M, Boyd L, Walker L.C. 16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010: Summary and conclusions. Br J Cancer 2011; 105 (Suppl. 2): 77-81. doi: 10.1038/bjc.2011.489
  8. Переверзев А.С., Щукин Д.В., Илюхин Ю.А., Мегера В.В. Оперативное лечение двустороннего почечно-клеточного рака. Урология. 2003; 2: 7-12.
  9. Liu H, Sundquist J, Hemminki K. Familial renal cell carcinoma from the Swedish Family-Cancer Database. Eur Urol 2011; 60 (5): 987-93. doi: 10.1016/j.eururo.2011.05.031

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies